Perez CA, Camel HM, Galakatos AE, et al. Results, complications, and dosimetric and surgical considerations. Rarely, surgery may be combined with the above. Perez CA, Camel HM, Galakatos AE, et al. Results, complications, and dosimetric and surgical considerations.
Standard treatment is inadequate.
In a large series only five of fifty patients with recurrence were salvaged by surgery or radiation therapy. Most recurrences are in the first 2 years after treatment. In centrally recurrent vaginal cancers, some patients may be candidates for pelvic exenteration or irradiation. Clinical trials are also appropriate and should be considered. Neither cisplatin nor mitoxantrone has significant activity in recurrent or advanced squamous cell cancer.